VARIABILITY IN THE ELIMINATION OF MIANSERIN IN ELDERLY PATIENTS

被引：18

作者：

BEGG, EJ

SHARMAN, JR

KIDD, JE

SAINSBURY, R

CLARK, DWJ

机构：

[1] CHRISTCHURCH HOSP,DEPT TOXICOL,CHRISTCHURCH,NEW ZEALAND

[2] PRINCESS MARGARET HOSP,DEPT GERIATR MED,CHRISTCHURCH 2,NEW ZEALAND

[3] UNIV OTAGO,DEPT PHARMACOL,DUNEDIN,NEW ZEALAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1989年 / 27卷 / 04期

关键词：

D O I：

10.1111/j.1365-2125.1989.tb05392.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：445 / 451

页数：7

共 21 条

[1] INFLUENCE OF AGE ON MIANSERIN PHARMACOKINETICS [J].

ALTAMURA, AC ;

MELORIO, T ;

INVERNIZZI, G ;

GOMENI, R .

PSYCHOPHARMACOLOGY, 1982, 78 (04) :380-382

[2] IMIPRAMINE DEMETHYLATION AND HYDROXYLATION - IMPACT OF THE SPARTEINE OXIDATION PHENOTYPE [J].

BROSEN, K ;

OTTON, SV ;

GRAM, LF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :543-549

[3] GENETICALLY-DETERMINED VARIABILITY IN ACETYLATION AND OXIDATION - THERAPEUTIC IMPLICATIONS [J].

CLARK, DWJ .

DRUGS, 1985, 29 (04) :342-375

[4]

CLINK HM, 1983, BRIT J CLIN PHARMACO, V15, pS291, DOI 10.1111/j.1365-2125.1983.tb05877.x

[5] PLASMA-CONCENTRATIONS OF MIANSERIN AFTER SINGLE DOSE AND AT STEADY-STATE IN DEPRESSED ELDERLY PATIENTS [J].

DAWLING, S ;

FORD, S ;

ARIYANAYAGAM, P ;

ONEAL, H ;

LEWIS, RR .

CLINICAL PHARMACOKINETICS, 1987, 12 (01) :73-78

[6]

EDWARDS IR, 1985, NEW ZEAL MED J, V98, P75

[7] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].

EICHELBAUM, M ;

SPANNBRUCKER, N ;

STEINCKE, B ;

DENGLER, HJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187

[8] POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].

EICHELBAUM, M ;

BERTILSSON, L ;

SAWE, J ;

ZEKORN, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186

[9]

GIBALDI M, 1982, PHARMACOKINETICS

[10]

Goodman A. G., 1985, PHARM BASIS THERAPEU

← 1 2 3 →